Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Rossi

Showing results (481-490 of 504) with videos related to

Pageof 51
Sort By:
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
American Journal of Hematology|April 20, 2021
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trialsFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
American Journal of Hematology|May 14, 2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, et al.
The Journal of Clinical Investigation|December 12, 2017
Drug-perturbation-based stratification of blood cancerSascha Dietrich, Małgorzata Oleś, Junyan Lu, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Blood Advances|May 27, 2026
Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevanceHelen Parker, Amatta Mirandari, Ben Stevens, et al.
Blood|May 13, 2025
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNAMaria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, et al.
Pageof 51

Showing results (481-490 of 504) with videos related to

Sort By:
Pageof 51
Blood|April 9, 2020
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemiaAdalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, et al.
American Journal of Hematology|April 20, 2021
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trialsFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
The Lancet. Oncology|May 31, 2024
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trialMoritz Fürstenau, Arnon P Kater, Sandra Robrecht, et al.
European Journal of Haematology|December 30, 2020
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, et al.
American Journal of Hematology|May 14, 2021
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia casesFortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, et al.
The Journal of Clinical Investigation|December 12, 2017
Drug-perturbation-based stratification of blood cancerSascha Dietrich, Małgorzata Oleś, Junyan Lu, et al.
Leukemia|April 24, 2025
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarkerBirna Thorvaldsdottir, Larry Mansouri, Lesley-Ann Sutton, et al.
Haematologica|August 3, 2019
Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemiaFary Diop, Riccardo Moia, Chiara Favini, et al.
Blood Advances|May 27, 2026
Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevanceHelen Parker, Amatta Mirandari, Ben Stevens, et al.
Blood|May 13, 2025
A Comprehensive Genetic Study of Classical Hodgkin Lymphoma Using Circulating Tumor DNAMaria Cristina Pirosa, Alessio Bruscaggin, Lodovico Terzi di Bergamo, et al.
Pageof 51